Germany Next-Generation Sequencing (NGS) Services Market (2017-2022)
The Germany Next-Generation Sequencing (NGS) Services Market was valued at $111.1 Million in 2017 and projected to reach to $290.7 Million by 2022, representing a compound annual growth rate of 21.2%. Germany's NGS services market is positioned for sustained growth through 2022 and beyond, driven by increasing healthcare investments, growing demand for personalized medicine, and expanding clinical applications of genomic sequencing.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Germany Next-Generation Sequencing (NGS) Services Market Trends and Insights
- This expansion reflects Germany's position as a leading European hub for genomic research and precision medicine adoption.
- Germany's strong healthcare infrastructure, coupled with significant investment in biotechnology and genomic research initiatives, has positioned the country as a key driver of NGS service demand across Europe. The 21.2% compound annual growth rate (CAGR) observed in Germany outpaces global trends, underscoring the nation's commitment to advancing personalized medicine and diagnostic capabilities.
- Germany's pharmaceutical and diagnostic sectors have increasingly integrated NGS technologies into clinical workflows, supporting cancer genomics, rare disease diagnosis, and pharmacogenomics applications.
- The market's trajectory from 2017 to 2022 reflects Germany's regulatory support for genomic medicine and the growing adoption of NGS services among hospitals, research institutions, and private diagnostic laboratories throughout the country..
Key Market Statistics
- CAGR (2017-2022) 21.2% CAGR
- Market Size, 2017 ~USD 111.1 Million
- Forecast, 2022 ~USD 290.7 Million
- Country Germany
Germany Next-Generation Sequencing (NGS) Services Market Overview
Rapid Market Expansion :
Germany's NGS services market grew from $111.1 million in 2017 to $290.7 million by 2022, representing a 21.2% CAGR and demonstrating strong adoption of genomic sequencing technologies across the country.
European Research Leadership :
Germany maintains a prominent position as a leading European hub for genomic research and precision medicine, supported by world-class research institutions and pharmaceutical companies investing heavily in NGS capabilities.
Healthcare Infrastructure Advantage :
Germany's robust healthcare system and regulatory framework provide a stable foundation for NGS service expansion, enabling seamless integration of advanced sequencing technologies into clinical diagnostics and research workflows.
Precision Medicine Adoption :
Increasing adoption of precision medicine approaches in German healthcare facilities drives demand for NGS services, particularly in oncology, rare disease diagnosis, and personalized treatment planning.
Germany Next-Generation Sequencing (NGS) Services Market Dynamics
- The country's strong pharmaceutical and biotechnology sectors continue to fuel innovation and service adoption across academic institutions, hospitals, and private diagnostic laboratories. Future growth will be supported by declining sequencing costs, regulatory harmonization within the EU, and rising awareness of genomic medicine among healthcare providers and patients.
- Germany's commitment to precision medicine initiatives and genomic research funding ensures continued market expansion and technological advancement in NGS service delivery..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Germany's NGS services market grew from $111.1M (2017) to $290.7M (2022), representing a 21.2% CAGR and outpacing global growth rates.
- Germany's advanced healthcare infrastructure and biotech investment ecosystem position the country as Europe's leading NGS services market.
- Clinical adoption of NGS in Germany spans oncology, rare disease diagnosis, and pharmacogenomics, driving service demand across multiple healthcare segments.
- Germany's regulatory framework and precision medicine initiatives support sustained NGS market expansion through 2022 and beyond.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
Germany Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- Pharmaceutical & Biotech Companies : German and international pharma firms need market intelligence to guide R&D investments, clinical trial strategies, and precision medicine partnerships within Germany's growing NGS ecosystem.
- Healthcare Providers & Hospitals : German hospital networks and diagnostic centers require market data to justify NGS service investments, benchmark against competitors, and plan genomic medicine program expansion.
- Diagnostic Laboratory Operators : Clinical and research laboratories in Germany need market sizing and growth forecasts to evaluate service expansion opportunities, technology upgrades, and competitive positioning in the NGS market.
- Medical Device & Technology Vendors : NGS equipment manufacturers and software providers need Germany-specific market insights to identify customer segments, forecast demand, and develop localized sales and support strategies.
- Healthcare Investors & Consultants : Private equity firms, venture capitalists, and management consultants require validated market data for Germany to evaluate investment opportunities and advise clients on genomic healthcare ventures.
Key Companies in the Germany Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for Germany's NGS services sector with verified CAGR of 21.2%, enabling accurate financial forecasting and investment decision-making for market entry or expansion strategies.
- Competitive Landscape Intelligence : Understand Germany's unique market dynamics, key players, and competitive positioning within Europe's genomic services ecosystem to identify partnership opportunities and differentiation strategies.
- Regional Growth Drivers Analysis : Access detailed insights into Germany-specific factors driving NGS adoption, including healthcare infrastructure strengths, regulatory environment, and precision medicine initiatives shaping market demand.
- Strategic Market Entry Planning : Leverage comprehensive Germany market data to develop targeted go-to-market strategies, identify high-potential customer segments, and allocate resources effectively for successful market penetration.
- Investment & Funding Decisions : Support capital allocation decisions with validated market forecasts and growth projections specific to Germany, enabling confident investment in NGS service infrastructure and technology development.
Frequently asked questions
What was Germany's NGS services market size in 2017?
Germany's NGS services market was valued at $111.1 million in 2017, establishing a strong baseline for subsequent growth through 2022.
What is the projected market size for Germany's NGS services by 2022?
Germany's NGS services market is forecasted to reach $290.7 million by 2022, reflecting significant expansion driven by clinical adoption and technological advancement.
What is Germany's NGS services market CAGR?
Germany's NGS services market is projected to grow at a compound annual growth rate of 21.2% between 2017 and 2022, outpacing global averages.
Which sectors drive NGS service demand in Germany?
Germany's NGS service demand is driven by oncology diagnostics, rare disease identification, pharmacogenomics, and research institutions leveraging precision medicine approaches.
Why is Germany a key NGS services market in Europe?
Germany's leadership in the European NGS market stems from its advanced healthcare infrastructure, substantial biotech investment, regulatory support for genomic medicine, and strong pharmaceutical sector integration.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
